Exact Mass: 631.337
Exact Mass Matches: 631.337
Found 232 metabolites which its exact mass value is equals to given mass value 631.337
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mesaconitine
Mesaconitine is a diterpenoid. Mesaconitine is a natural product found in Aconitum anthora, Aconitum napellus, and other organisms with data available. Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid Annotation level-1 Mesaconitine is the main active component of genus aconitum plants. IC50 value: Target: in vitro: In HUVECs, 30 microM mesaconitine increased the [Ca(2+)](i) level in the presence of extracellular CaCl(2) and NaCl, and the response was inhibited by KBR7943. Mesaconitine increased intracellular Na(+) concentration level in HUVECs. The [Ca(2+)](i) response by mesaconitine was inhibited by 100 microM D-tubocurarine [1]. Mesaconitine at 30 microM inhibited 3 microM phenylephrine-induced contraction in the endothelium-intact, but not endothelium-denuded, aortic rings [2]. MA promoted the alpha-MT-induced decrease in NE levels in hippocampus, medulla oblongata plus pons and spinal cord [3]. Mesaconitine is the main active component of genus aconitum plants. IC50 value: Target: in vitro: In HUVECs, 30 microM mesaconitine increased the [Ca(2+)](i) level in the presence of extracellular CaCl(2) and NaCl, and the response was inhibited by KBR7943. Mesaconitine increased intracellular Na(+) concentration level in HUVECs. The [Ca(2+)](i) response by mesaconitine was inhibited by 100 microM D-tubocurarine [1]. Mesaconitine at 30 microM inhibited 3 microM phenylephrine-induced contraction in the endothelium-intact, but not endothelium-denuded, aortic rings [2]. MA promoted the alpha-MT-induced decrease in NE levels in hippocampus, medulla oblongata plus pons and spinal cord [3].
Gliadins
Isolated from wheat flour or wheat gluten
Mesaconitine
PC(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
PC(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0)
PC(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
(32S,6S)-6-benzyl-31-[N-(N,N-dimethyl-L-leucyl)-L-isoleucyl]-(32rH,33tH)-2-oxa-5,8-diaza-1(1,4)-benzena-3(3,2)-pyrrolidina-cyclodecaphan-9c-ene-4,7-dione|Amphibin C|amphibine-C
(32S,6S)-6-(S)-sec-butyl-31-[N-(N,N-dimethyl-L-phenylalanyl)-L-isoleucyl]-(32rH,33tH)-2-oxa-5,8-diaza-1(1,4)-benzena-3(3,2)-pyrrolidina-cyclodecaphan-9c-ene-4,7-dione|Amphibin D|amphibine-D
(25S)-16alpha-acetoxy-3beta-beta-D-glucopyranosyloxy-16,28-seco-solanida-5,22(28)-dien-24-one|Veralodinin|veralodinine
Asp Arg Arg Trp
Asp Arg Trp Arg
Asp Trp Arg Arg
Phe Phe Arg Tyr
Phe Phe Tyr Arg
Phe Arg Phe Tyr
Phe Arg Tyr Phe
Phe Tyr Phe Arg
Phe Tyr Arg Phe
Ile Lys Trp Trp
Ile Gln Trp Trp
Ile Trp Lys Trp
Ile Trp Gln Trp
Ile Trp Trp Lys
Ile Trp Trp Gln
Lys Ile Trp Trp
Lys Leu Trp Trp
Lys Trp Ile Trp
Lys Trp Leu Trp
Lys Trp Trp Ile
Lys Trp Trp Leu
Leu Lys Trp Trp
Leu Gln Trp Trp
Leu Trp Lys Trp
Leu Trp Gln Trp
Leu Trp Trp Lys
Leu Trp Trp Gln
Gln Ile Trp Trp
Gln Leu Trp Trp
Gln Trp Ile Trp
Gln Trp Leu Trp
Gln Trp Trp Ile
Gln Trp Trp Leu
Arg Asp Arg Trp
Arg Asp Trp Arg
Arg Phe Phe Tyr
Arg Phe Tyr Phe
Arg Arg Asp Trp
Arg Arg Trp Asp
Arg Trp Asp Arg
Arg Trp Arg Asp
Arg Tyr Phe Phe
Trp Asp Arg Arg
Trp Ile Lys Trp
Trp Ile Gln Trp
Trp Ile Trp Lys
Trp Ile Trp Gln
Trp Lys Ile Trp
Trp Lys Leu Trp
Trp Lys Trp Ile
Trp Lys Trp Leu
Trp Leu Lys Trp
Trp Leu Gln Trp
Trp Leu Trp Lys
Trp Leu Trp Gln
Trp Gln Ile Trp
Trp Gln Leu Trp
Trp Gln Trp Ile
Trp Gln Trp Leu
Trp Arg Asp Arg
Trp Arg Arg Asp
Trp Trp Ile Lys
Trp Trp Ile Gln
Trp Trp Lys Ile
Trp Trp Lys Leu
Trp Trp Leu Lys
Trp Trp Leu Gln
Trp Trp Gln Ile
Trp Trp Gln Leu
Tyr Phe Phe Arg
Tyr Phe Arg Phe
Tyr Arg Phe Phe
Gliadin
Mgb-BP-3
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D004214 - Distamycins
Indinavir hydrate
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
(E)-(4S,6S)-6-((S)-2-{(S)-2-[(Furan-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyrylamino)-8-methyl-5-oxo-4-((R)-2-oxo-pyrrolidin-3-ylmethyl)-non-2-enoic acid ethyl ester
soyasapogenol E 3-O-beta-glucuronate
A monocarboxylic acid anion that results from the removal of a proton from the carboxy group of soyasapogenol E 3-O-beta-glucuronide.
6-[(3S,6S,9S,12R)-3-benzyl-6-[(1-methoxyindol-3-yl)methyl]-2,5,8,11-tetraoxo-1,4,7,10-tetrazabicyclo[10.3.0]pentadecan-9-yl]hexanoic acid
2-amino-3-[[2-decanoyloxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-decoxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-heptanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2E,6S,8Z,10E,12S,14S,15R)-3-hexyl-12,14-dihydroxy-15-methyl-6-[(1S,2R,5E,7E)-1,2,4-trihydroxy-3,5,7-trimethylnona-5,7-dienyl]-5-oxa-17-thia-19-azabicyclo[14.2.1]nonadeca-1(18),2,8,10,16(19)-pentaen-4-one
2-amino-3-[[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(1r,2s,3s,5r,7s,10s,11s,12s,15r,16s,17r,19s)-8-ethyl-15,17-dihydroxy-3,12,16-trimethoxy-10-(methoxymethoxy)-6-oxa-8-azahexacyclo[15.2.1.0²,⁷.0²,¹¹.0⁵,¹⁰.0¹⁴,¹⁹]icos-13-en-18-yl 4-methoxybenzoate
(1s,2r,3r,4r,5r,6s,7s,8r,9r,10r,13r,14r,16s,17s,18r)-8-(acetyloxy)-11-ethyl-5,7,14,16-tetrahydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate
23-(1,2-dihydroxy-3-methylpent-3-en-1-yl)-2,21,22-trihydroxy-5,7,13,20-tetramethyl-14,25-dioxa-24-azapentacyclo[22.2.2.0³,¹².0⁴,⁹.0¹³,¹⁵]octacosa-1,10-diene-26,27-dione
(3s,4r,5r,7s,9r,12s,13s,15s,20s,21r,22r,23r)-23-[(1r,2s)-1,2-dihydroxy-3-methylpent-3-en-1-yl]-2,21,22-trihydroxy-5,7,13,20-tetramethyl-14,25-dioxa-24-azapentacyclo[22.2.2.0³,¹².0⁴,⁹.0¹³,¹⁵]octacosa-1,10-diene-26,27-dione
6-(1,3-dihydroxy-2,4,6-trimethylocta-4,6-dien-1-yl)-3-hexyl-7,13,15-trihydroxy-16-methyl-5-oxa-18-thia-20-azabicyclo[15.2.1]icosa-1(19),2,9,11,17(20)-pentaen-4-one
(2s,3r)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-2-(dimethylamino)-3-methylpentanimidic acid
11-ethyl-5,14-dihydroxy-6,8,16,18-tetramethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate
9-hexyl-7,15,18-trihydroxy-19-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-2-methyl-9h,10h,12h,13h,14h,15h,16h,19h,20h,20ah-cyclopenta[i]azacyclononadecane-11,17-dione
8-(acetyloxy)-11-ethyl-5,7,14,16-tetrahydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate
amphibin d
{"Ingredient_id": "HBIN015904","Ingredient_name": "amphibin d","Alias": "NA","Ingredient_formula": "C36H49N5O5","Ingredient_Smile": "CCC(C)C1C(=O)NC=CC2=CC=C(C=C2)OC3CCN(C3C(=O)N1)C(=O)C(C(C)CC)NC(=O)C(CC4=CC=CC=C4)N(C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25581","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
amphibine D
{"Ingredient_id": "HBIN015906","Ingredient_name": "amphibine D","Alias": "amphibine d","Ingredient_formula": "C36H49N5O5","Ingredient_Smile": "CCC(C)C1C(=O)NC=CC2=CC=C(C=C2)OC3CCN(C3C(=O)N1)C(=O)C(C(C)CC)NC(=O)C(CC4=CC=CC=C4)N(C)C","Ingredient_weight": "631.8","OB_score": "17.86528711","CAS_id": "38496-02-5","SymMap_id": "SMIT03945","TCMID_id": "1081","TCMSP_id": "MOL001550","TCM_ID_id": "NA","PubChem_id": "12306074","DrugBank_id": "NA"}